Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (21257)	9/14/2006 10:40:29 PM
From: ghmm	Read Replies (1) \| Respond to of 52153

rkrw, SO I am not the only one waiting for them to make their IPO!! :). I was a shareholder of TKT (before Shire takeover) and hold Biomarin. I think a small molecule in the MPS area would be a great improvement for patients and offer a lot of potential. If my memory is correct isn't the CEO the one who (at another company) got the Pompe drug moving along (before selling out to Genzyme). I believe it was him, see recent WSJ article about new book. If your not familiar with it, nice article believe he has 2 children with the disease oh and btw, Amicus is working on a Pompe drug... Yeah wouldn't be surprised if your right and Genzyme has a thing or two to do with it. Maybe they (Amicus) could recruit Michael Astrue to a mgm post.